Ticker Symbol: DVAX
Dynavax Technologies Corp.
$17.16 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001029142
Company Profile
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 2100 Powell Street
Website: http://www.dynavax.com/
CEO: Ryan Spencer
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $14.41
Change:
-$0.56
(
-3.81%)
Days Range: $14.29 - $14.90
Beta: 1.22
52wk. High: $15.12
52wk. Low: $9.42
Ytd. Change 36.98%
50 Day Moving Average: $14.16
200 Day Moving Average: $12.97
Shares Outstanding: 128797357
Valuation
Market Cap: 185.6B
PE Ratio: 19.04
EPS (TTM): 0.7569
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A